Advertisement
UK markets closed
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • CRUDE OIL

    82.94
    -0.42 (-0.50%)
     
  • GOLD FUTURES

    2,335.10
    -7.00 (-0.30%)
     
  • DOW

    38,487.91
    -15.78 (-0.04%)
     
  • Bitcoin GBP

    51,621.91
    -1,785.30 (-3.34%)
     
  • CMC Crypto 200

    1,390.60
    -33.50 (-2.35%)
     
  • NASDAQ Composite

    15,721.95
    +25.31 (+0.16%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

EU backs AstraZeneca's drug for prevention of infant RSV

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York, United States

(Reuters) - AstraZeneca said on Friday its drug for preventing infant RSV, Beyfortus (nirsevimab), was recommended for approval in the European Union by a European Medicines Agency committee.

The drugmaker also said if Beyfortus is approved, it would become the first protective option for newborn and infant population against RSV lower respiratory tract disease.

(Reporting by Amna Karimi in Bengaluru; editing by Uttaresh.V)